ArticleFrontiers in immunology2025
Low maternal pertussis protection and quantified infant risk: supporting maternal Tdap vaccination in China.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Investigation and analysis of pertussis antibody levels among healthy people in Hangzhou, Zhejiang Province from 2021 to 2024.Frontiers in public health · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Pertussis remains a significant threat to infants, particularly in settings like China, where maternal tetanus-diphtheria-acellular pertussis (Tdap) vaccination is not part of the National Immunization Program, and data on maternal pertussis immunity are limited. This study aimed to assess the seroprevalence of protective pertussis toxin (PT) IgG antibodies in pregnant women and quantify the potential risk of infant pertussis under varying epidemiological scenarios. Methods: A cross-sectional serosurvey was conducted among 1,205 pregnant women in Jiangsu Province, China, from January to December 2024. Serum anti-PT IgG concentrations were measured using ELISA, with a protective threshold defined as ≥40 IU/mL. A scenario-based risk model ( Results: The overall median anti-PT IgG concentration was 6.34 IU/mL (IQR: 4.24-11.16), with only 3.57% (95% CI: 2.66-4.77%) of women achieving the protective threshold (≥40 IU/mL). Under a representative scenario ( Conclusion: Low maternal pertussis immunity in China poses a quantifiable risk to infants, particularly under elevated incidence scenarios. Maternal Tdap vaccination could substantially reduce infant pertussis burden, supporting its consideration for national immunization policy. These findings provide critical evidence for addressing immunity gaps and protecting vulnerable newborns in China.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.